B of A Securities Maintains Buy on Cellebrite DI, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Tal Liani maintains a Buy rating on Cellebrite DI (NASDAQ:CLBT) and raises the price target from $13 to $17.
August 16, 2024 | 5:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities analyst Tal Liani maintains a Buy rating on Cellebrite DI and raises the price target from $13 to $17.
The Buy rating and increased price target from a reputable analyst at B of A Securities is likely to positively impact investor sentiment and drive short-term price appreciation for CLBT.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100